Evaluation of ADC values in *IDH 1 gene mutation* Vs *IDH 1 mutation negative* Gliomas

Authors:
Dr. Prasad Hanagandi, Dr. Rafael Glikstein, Dr Thanh Nguyen

Purpose:
Recent advances in tumor genomics have shown that biologic behavior of glial neoplasms depends on IDH1-R132H (isocitrate dehydrogenase) status. IDH1-R132H-positive tumors respond more effectively to treatment and have an overall better outcome.
To evaluate the ADC values between *IDH 1 gene mutation* Vs *IDH 1 mutation negative* Gliomas.

Methods: The study involves a retrospective analysis of gliomas retrieved from PACS (Picture Archiving Communication System). To improve the efficacy of the study preoperative MRI scans were retrospectively analyzed to measure the ADC values without taking into consideration the IDH1 status.
Total of 36 cases were evaluated 21 IDH1 gene mutation negative and 15 IDH1 gene mutation negative were assessed.

Results:
Preliminary data indicates that IDH1 mutation tumors have higher ADC values as compared to IDH1 mutation negative gliomas.